Combining BET inhibitors and PARP inhibitors might help patients resistant to chemotherapy, the study suggests.

Bristol Myers (BMY)’ treatment of small cell lung cancer, atigotatug plus nivolumab fixed dose combination, received FDA ...

About 2 in 3 people with SCLC have extensive disease when they first get diagnosed. Treatment can’t cure the disease, but it could ease your symptoms and help you live longer. Standard treatment ...

How Do You Treat SCLC and NSCLC? There are different options for treating lung cancer. The treatment you get depends on the type and stage of your lung cancer, and other factors like your age and ...

Scientists found that aggressive lung cancer cells create their own electrical network, helping them spread. This unique ...

Small cell lung cancer (SCLC) is one of the most recalcitrant cancers. SCLC patients usually present with extensive ...

As an expert explained in an interview with CURE, we may be in the midst of a “new era” for small cell lung cancer research.

Findings on golidocitinib for patients with non-small cell lung cancer whose disease has progressed on anti-PD-1 therapy will ...

There are other less common types of non-small cell lung cancer that can begin in any part of the lung. Treatment options include surgery, immunotherapy, chemotherapy, radiation, or a combination of ...

Non-small cell lung cancer that has metastasized may cause different symptoms depending on where it has spread. Treatment can help reduce symptoms and prolong life. Non-small cell lung cancer ...

In this cohort study, geographic access to cancer care was associated with guideline-recommended treatment for early-stage non–small cell lung cancer (NSCLC) and outcomes, particularly in socially ...